




OXSTEM



OXSTEM  
CARDIO

**OxStem Limited Establishes A Fourth New Subsidiary Company:  
'OxStem Cardio'**

**17<sup>th</sup> November 2016**

OxStem Ltd today launched its fourth subsidiary company – OxStem Cardio. Following the spin-out of OxStem Ltd from the University of Oxford in May 2016, the company has already established three subsidiaries each with a specific disease focus: OxStem Oncology, OxStem Neuro and OxStem Ocular. OxStem Cardio is the latest addition to the portfolio, set up with the intention of treating heart disease. The new subsidiary is cofounded by four pioneering scientists; chemists Prof Steve Davies and Prof Angela Russell are joined by cardiovascular and stem cell experts Prof Paul Riley and Prof Roger Patient.

A major aim of OxStem Cardio is to restore lost tissue following a heart attack by inducing cardiovascular regeneration using small molecules, in order to improve cardiac function. Prof Paul Riley, British Heart Foundation Professor of Regenerative Medicine, described the project as “an exciting first step towards a standard treatment for heart attack sufferers”. Prof Roger Patient, Professor of Developmental Genetics at the Weatherall Institute of Molecular Medicine in the Radcliffe Department of Medicine, added “this is a scientifically logical application of OxStem’s in depth knowledge of stem and progenitor cell function that could have real benefits for patients in the future.”

This work will be the next project funded within the University from OxStem’s record £16.9M initial fundraise. Dr Carolyn Porter, Deputy Head of Technology Transfer at Oxford University Innovation and OxStem board member said “we are extremely pleased to have continued to support OxStem with their exciting and ambitious work. Establishment of OxStem Cardio represents the latest crystallisation of their drive to innovate the regenerative medicine field.”

Dr Michael Stein, OxStem CEO, thanked all collaborators, investors and supporters for their continued enthusiasm: “we are thankful to all those who share and support our vision to revolutionise medicine and help patients, and are thrilled to be moving into the cardiovascular space with our new subsidiary OxStem Cardio”.

**Media enquiries to:**

Dr. Michael Stein,  
Chairman and CEO  
OxStem Limited  
[info@oxstem.co.uk](mailto:info@oxstem.co.uk)